ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 997

2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria

Frederick Wolfe1, Daniel J. Clauw2, MaryAnn FitzCharles3, Don Goldenerberg4, Winfried Häuser5, Robert S. Katz6, I Jon Russell7, Philip J. Mease8, Anthony Russell9 and Brian Walitt10, 1National Data Bank, Wichita, KS, 2Chronic Pain & Fatigue Research Center, University of Michigan, Ann Arbor, MI, 3Rheumatology, McGill University, Montreal, QC, Canada, 4Newton-Wellesley Hospital and Tufts University School of Medicine, Newton, MA., Newton, MA, 5Department of Psychosomatic Medicine and Psychotherapy, Technische Universität München, Munich, Germany, 6Rush University Medical Center, Chicago, IL, 7Arthritis & Osteoporosis Ctr of South Texas, San Antonio, TX, 8Swedish Medical Center and University of Washington, Seattle, WA, 9Medicine, University of Alberta, Edmonton, AB, Canada, 10National Institutes of Health, National Institute of Nursing Research, Bethesda, DC

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: fibromyalgia

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: The provisional criteria of the ACR 2010 and the 2011 self-report modification for survey and clinical research are valid, reliable and widely used for fibromyalgia diagnosis. In this 2016 fibromyalgia criteria update, we address identify problems and provide further guidelines for use.

Methods: Based on analysis of criteria studies and clinician and researchers comments, we identified problematic areas, including a) misclassification in asymmetric pain disorders, b) inconsistent and unclear instructions in the presence of other medical conditions, c) different clinician (2010) and self-report criteria (2011), d) unclearly defined pain assessment regions.

Results: Based on the above data and clinic usage data, we developed a (2016) revision of the 2010/2011 fibromyalgia criteria. Fibromyalgia may now be diagnosed in adults when all of the following criteria are met:

1) Widespread pain index (WPI) ≥7 and symptom severity scale (SSS) score ≥5 OR WPI 4–6 and SSS score ≥9.

2) Generalized pain, defined as pain in at least 4 of 5 regions, is present.

3) Symptoms have been present at a similar level for at least 3 months.

4) A diagnosis of fibromyalgia is valid irrespective of other diagnoses. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses.

The revision makes the following changes:

1) Changes criterion 1 to “Widespread pain index (WPI) ≥7 and Symptom Severity Scale (SSS) score ≥5 OR WPI 4–6 and SSS score ≥9.” (WPI minimum must be ≥4 instead of previous ≥3)

2) Adds a generalized pain criterion (Criterion 2) that is defined as pain in at least 4 of 5 regions (Left upper, right upper, left lower, right lower, axial). In this definition, jaw, chest and abdominal pain are not evaluated as part of the generalized pain definition.

3. Standardizes and makes 2010 and 2011 criterion (criterion 3) wording the same: “Symptoms have been generally present for at least 3 months.”

4) Removes the exclusion regarding disorders that could (sufficiently) explain the pain (criterion 4) and adds the following text: “A diagnosis of fibromyalgia is valid irrespective of other diagnoses. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses.”

5) Adds the Fibromyalgia Symptom (FS) [or polysymptomatic distress (PSD)] scale as a full component of the fibromyalgia criteria.

6) Creates one set of criteria (2016) instead of having separate physician (2010) and patient (2011) criteria by replacing the physician estimate of somatic symptom burden with ascertainment of the presence of headaches, pain or cramps in lower abdomen, and depression during the previous 6 months.

Conclusion: This revision combines physician and questionnaire criteria, minimizes misclassification of regional pain disorders, and eliminates the previously confusing recommendation regarding diagnostic exclusions. The physician-based criteria are valid for individual patient diagnosis. The self report version of the criteria are not valid for clinical diagnosis in individual patients, but are valid for research studies. The changes to the criteria allow them to function as diagnostic criteria, while still being useful for classification.


Disclosure: F. Wolfe, None; D. J. Clauw, Pfizer, Lilly, Tonix, Zynerba, Apptinix, Cerephex, IMC, 5,Paizer, Lilly, Cerephex, Tonix, 2; M. FitzCharles, None; D. Goldenerberg, None; W. Häuser, None; R. S. Katz, None; I. J. Russell, None; P. J. Mease, Abbvie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB Pharma, 2,Abbive, Amgen, BMS, Celgene, Crescendo, Corrona, Dermira, Janssen, Lilly, Merck, Novartis, Pfizer, Sun, UCB Pharma, Zynerba, 5,Abbvie, Amgen, BMS, Celgene, Crescendo, Genentech, Janssen, Novartis, Pfizer, UCB Pharma, 8; A. Russell, None; B. Walitt, None.

To cite this abstract in AMA style:

Wolfe F, Clauw DJ, FitzCharles M, Goldenerberg D, Häuser W, Katz RS, Russell IJ, Mease PJ, Russell A, Walitt B. 2016 Revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/2016-revisions-to-the-20102011-fibromyalgia-diagnostic-criteria/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/2016-revisions-to-the-20102011-fibromyalgia-diagnostic-criteria/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology